-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NFX-179 in Neurofibromatoses Type I (Von Recklinghausen’s Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NFX-179 in Neurofibromatoses Type I (Von Recklinghausen's Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NFX-179 in Neurofibromatoses Type I (Von Recklinghausen's Disease)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NFX-179 in Neurofibromatoses Type I (Von Recklinghausen’s Disease)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NFX-179 in Neurofibromatoses Type I (Von Recklinghausen’s Disease) Drug Details: NFX-179 is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – NFX-179
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry NFX-179 Drug Details NFX-179 is under development for the treatment of neurofibromatosis type 1,...
-
Product Insights
Neurofibromatoses Type I (Von Recklinghausen’s Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Neurofibromatosis type 1 (NF1) is also called von Recklinghausen's disease. It is a rare genetic disorder characterized by the development of multiple noncancerous (benign) tumors of nerves and skin (neurofibromas). This is transmitted on chromosome 17 and is caused by a mutation of the NF1 gene. Symptoms include liver enlargement, glioma, Lisch nodules, and pheochromocytoma. Treatment includes pain medications, surgery, chemotherapy, and radiation therapy. The NF1 pipeline market research report provides comprehensive information on the therapeutics under development for NF1,...